Superselective intra-arterial cisplatin infusion and concomitant radiotherapy (RADPLAT) for maxillary sinus squamous cell carcinoma: an institutional experience of 118 cases
This retrospective study of 118 patients demonstrates that superselective intra-arterial cisplatin infusion with concomitant radiotherapy (RADPLAT) offers favorable long-term survival and acceptable toxicity for selected maxillary sinus squamous cell carcinoma patients, particularly those without lymph node metastases, positioning it as a promising alternative to radical surgery.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine you are trying to put out a fire inside a very delicate, crowded house. The house is your body, and the fire is a stubborn tumor growing in the maxillary sinus—a hollow space behind your cheekbone. Usually, the standard way to fight this fire is to bring in the heavy machinery: surgeons who might have to remove large parts of the face to get the tumor out, followed by radiation to clean up the sparks. While this works, it can leave the "house" looking very different and feeling quite broken, affecting how you eat, speak, and see.
For years, doctors have tried a different approach: sending firefighters (chemotherapy drugs) through the main water pipes (veins) that feed the whole neighborhood. But the water pressure is often too weak to douse a fierce fire, and the water dilutes before it even reaches the blaze. This new paper explores a more targeted strategy called RADPLAT. Think of this as sending a specialized fire hose directly into the specific pipe feeding the burning room. By injecting a high dose of the drug "cisplatin" right into the artery feeding the tumor, while simultaneously blasting the area with radiation, doctors hope to smother the fire with maximum force while sparing the rest of the house. The big question is: does this super-targeted hose work better than the standard methods, and does it cause too much damage to the pipes themselves?
This study, conducted by a team at Hokkaido University in Japan, looks back at 118 patients who chose this "super-targeted hose" method (RADPLAT) as their first line of defense against maxillary sinus squamous cell carcinoma between 1999 and 2021. The researchers wanted to see how these patients fared over the long haul and what kind of side effects they experienced.
The results suggest that this approach is a powerful tool for the right patients. The team found that 5 years after treatment, about 69.5% of the patients were still alive, and roughly 59.4% were free from the cancer returning in that specific spot. The study highlights that the treatment worked best for patients who didn't have the cancer spread to their lymph nodes and for those who were younger. Interestingly, the number of times patients received the drug infusion mattered; those who managed to complete more cycles of the treatment (six or more) tended to have better outcomes. The authors suggest that this method offers a promising alternative to radical surgery for selected patients, potentially saving them from the heavy cosmetic and functional toll of removing large parts of the face.
However, the "fire hose" isn't without its risks. The study notes that the treatment is intense. More than half of the patients (53.4%) experienced severe short-term side effects, such as low white blood cell counts, severe mouth sores, and anemia. In the long run, about 30% of patients faced late complications. The most serious of these involved damage to the eyes (which could lead to blindness in some cases) and the jawbone, where the bone could die and require complex reconstruction surgery. In rare but tragic cases, the treatment led to brain abscesses or necrosis.
The paper also points out what this method doesn't do. It doesn't seem to work as well for patients whose cancer has already spread to the lymph nodes in the neck; these patients had significantly worse survival rates. The authors also caution that while the results look good, this was a look-back study at one hospital, not a head-to-head race against other treatments. They suggest that while RADPLAT is a viable and effective option for specific cases—especially those who want to avoid major surgery or have tumors that are hard to cut out—we still need more direct comparisons to know exactly where it fits in the big picture of cancer care. Ultimately, the study paints a picture of a high-stakes, high-reward strategy that can save lives and preserve faces, but it demands careful patient selection and a willingness to manage significant side effects.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.